MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson’s Disease

    G. Padoani, S. Novello, C. Pisanò, C. Caccia, E. Melloni, S. Vailati, C. Keywood, M. Morari (Bresso (Milan), Italy)

    Objective: To evaluate whether safinamide inhibits in vivo glutamate (Glu) release in a rodent model of Parkinson’s disease (PD), i.e. the 6-hydroxydopamine (6-OHDA) hemilesioned rat.…
  • 2018 International Congress

    Abrogation of Rotenone Induced Behavior, Biochemical and Mitochondrial Deficits in Mice by Curcumin and Ginkgo Biloba: New Combinational Therapy Approach for Parkinson’s Disease

    D. Khatri, M. Panchwadkar, P. Rane, V. Undale (Pune, India)

    Objective: This study was designed with the objective to find out the possible synergistic effect of Curcumin (Cur) and Methanolic extract of Ginkgo biloba (EGB)…
  • 2018 International Congress

    Delivery of AAV alpha synuclein to a mouse and rat provides a useful model for the assessment of anti-parkinsonian efficacy of chronic inhibition of LRRK2

    R. Hodgson, T. Parkkari, T. Martinez, M. Fell, D. Bryce, T. Heikkinen, A. Nurmi, T. Bragge, M. Taavitsainen, T. Lanz, M. Baptista (Wilmington, MA, USA)

    Objective: 1. To create an in vivo model system to be used to assess the effect of chronically inhibiting LRRK2 pharmacologically. 2. To confirm previous…
  • 2018 International Congress

    Artisanal formulations of Cannabis in Movement Disorders. The real-life perspective in a population from Buenos Aires, Argentina. Preliminary report

    M. Cesarini, JL. Etcheverry, N. Gonzalez Rojas, G. Da Prat, V. Parisi, G. Rojas, G. Persi, E. Gatto (Buenos Aires, Argentina)

    Objective: To describe the effect of artisanal formulations of CBDo in a retrospective case series of patients with a variable spectrum of movement disorders, who…
  • 2018 International Congress

    Ginsenoside Rb1 protects dopaminergic neurons through Foxm1-Nurr1 pathway in mice model of Parkinson’s disease

    T. Zhou, X. Huang, L. Li, J. Yang, Z. Liang (Dalian, China)

    Objective: In the present work, we investigated the protective effects of ginsenoside Rb1 in dopaminergic neurons through Foxm1-Nurr1 pathway in mice model of Parkinson’s disease.…
  • 2018 International Congress

    Neuromodulatory properties of flavonoids from Persea americana Peel: Role in CNS redox homeostasis and neurobehavioral markers

    S. Grace SR, PR, J. Chauhan, G. Chandran (Mys, India)

    Objective: Isolating flavonoids from Peel of Persea americana fruits & testing their effects on CNS redox homeostasis culminating in neurobehavioural amelioration among rats. Background: Cellular…
  • 2018 International Congress

    Neuromodulatory propensity of Ginko biloba to offset rotenone induced behaviour and biochemical alteration

    K. Rode, D. Khatri, M. Panchawadkar, P. Rane (Pune, India)

    Objective: The aim of present study was to evaluate neuromodulatory propensity of Gingko Biloba in rotenone induced Mice Model of Parkinson Disease in terms of…
  • 2018 International Congress

    Economics of Botulinum Toxin Therapy: Influence of the AbobotulinumtoxinA Package Size on the Costs of Botulinum Toxin Therapy

    F. Adib Saberi, D. Dressler (Hamburg, Germany)

    Objective: To explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic (>9000…
  • 2018 International Congress

    Could curcumin be the preventive key of parkinson’s disease?

    W. Laabbar, A. Elgot, H. Gamrani (Marrakech, Morocco)

    Objective: The present study evaluates the possible protective effect of curcumin on rats exposed to aluminum which is a major risk factor of parkinson's disease.…
  • 2018 International Congress

    Long Term Response to L-dopa in Parkinson Disease

    H. Gupta, N. Wachter, K. Lyons, R. Pahwa (Kansas, KS, USA)

    Objective: To assess the long-term effectiveness of levodopa in Parkinson’s disease (PD) patients. Background: To date, levodopa continues to be the most efficacious drug in…
  • « Previous Page
  • 1
  • …
  • 1419
  • 1420
  • 1421
  • 1422
  • 1423
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley